Ronapreve (REGN-CoV; casirivimab and imdevimab) reduces the viral burden and alters the pulmonary response to the SARS-CoV-2 Delta variant (B.1.617.2) in K18-hACE2 mice using an experimental design reflective of a treatment use case
Microbiology Spectrum · 2024
DOI: 10.1128/spectrum.03916-23 ↗Kurz gefasst
Fachartikel in der Zeitschrift Microbiology Spectrum, 2024. Verfasst von Lee Tatham und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Therapeutics, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, United King…. Hauptthemen laut MEDLINE: SARS-CoV-2, COVID-19, Lung, COVID-19 Drug Treatment. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, Unitaid, UKRI | Engineering and Physical Sciences Research Council (EPSRC).
Abstract (Originalsprache)
With some exceptions, global policymakers have recommended against the use of existing monoclonal antibodies in COVID-19 due to loss of neutralization of newer variants. The purpose of this study was to investigate the impact of Ronapreve on compartmental viral replication using paradigms for susceptible and insusceptible variants. Virological efficacy and impact on pathogenicity was assessed in K18-hACE2 mice inoculated with either the Delta or BA.1 Omicron variants. Ronapreve reduced sub-genomic viral RNA levels in lung and nasal turbinate, 4 and 6 days post-infection, for the Delta variant but not the Omicron variant. It also blocked brain infection, which is seen with high frequency in K18-hACE2 mice after Delta variant infection. At day 6, the inflammatory response to lung infection with the Delta variant was altered to a multifocal granulomatous inflammation in which the virus appeared to be confined. The current study provides evidence of an altered tissue response to SARS-CoV-2 after treatment with a monoclonal antibody combination that retains neutralization activity. These data demonstrate that experimental designs that reflect treatment use cases are achievable in animal models for monoclonal antibodies. Extreme caution should be taken when interpreting prophylactic experimental designs that may not be representative of treatment. IMPORTANCE Following the emergence of the SARS-CoV-2 Omicron variant, the WHO recommended against the use of Ronapreve in its COVID-19 treatment guidelines due to a lack of efficacy based on current pharmacokinetic-pharmacodynamic understanding. However, the continued use of Ronapreve, specifically in vulnerable patients, was advocated by some based on in vitro neutralization data. Here, the virological efficacy of Ronapreve was demonstrated in both the lung and brain compartments using Delta as a paradigm for a susceptible variant. Conversely, a lack of virological efficacy was demonstrated for the Omicron variant. Comparable concentrations of both monoclonal antibodies were observed in the plasma of Delta- and Omicron-infected mice. This study made use of a reliable murine model for SARS-CoV-2 infection, an experimental design reflective of treatment, and demonstrated the utility of this approach when assessing the effectiveness of monoclonal antibodies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology and Therapeutics, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, United Kingdom.
- Centre of Excellence in Long-acting Therapeutics (CELT), University of Liverpool, Liverpool, United Kingdom.
- Laboratory for Animal Model Pathology, Institute of Veterinary Pathology, Vetsuisse Faculty, University of Zurich, Zurich, Switzerland.
- Department of Infection Biology & Microbiomes, Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool, United Kingdom.
- Department of Chemistry, University of Liverpool, Liverpool, United Kingdom.
ORCID-Profile: Lee Tatham, Anja Kipar, Rajith Kumar Reddy Rajoli, Steve Rannard, Andrew Owen
Förderung
- NIAID NIH HHS
- Unitaid
- UKRI | Engineering and Physical Sciences Research Council (EPSRC)
- European Union & Horizon Europe research and innovation program
- UKRI | Innovate UK
- Swiss State Secretariat for Education, Research and Innovation (SERI)
- Wellcome Trust (WT)
- Swiss National Science Foundation (SNSF)
Zitieren
APA
Tatham, L., Kipar, A., Sharp, J., Kijak, E., Herriott, J., Neary, M., Box, H., Gallardo Toledo, E., Valentijn, A., Cox, H., Pertinez, H., Curley, P., Arshad, U., Rajoli, R. K. R., Rannard, S., Stewart, J. P., & Owen, A. (2024). Ronapreve (REGN-CoV; casirivimab and imdevimab) reduces the viral burden and alters the pulmonary response to the SARS-CoV-2 Delta variant (B.1.617.2) in K18-hACE2 mice using an experimental design reflective of a treatment use case. Microbiology Spectrum. https://doi.org/10.1128/spectrum.03916-23
Vancouver
Tatham L, Kipar A, Sharp J, Kijak E, Herriott J, Neary M, et al. Ronapreve (REGN-CoV; casirivimab and imdevimab) reduces the viral burden and alters the pulmonary response to the SARS-CoV-2 Delta variant (B.1.617.2) in K18-hACE2 mice using an experimental design reflective of a treatment use case. Microbiology Spectrum. 2024. doi:10.1128/spectrum.03916-23
BibTeX
@article{Tatham2024,
author = {Tatham, Lee and Kipar, Anja and Sharp, Jo and Kijak, Edyta and Herriott, Joanne and Neary, Megan and Box, Helen and Gallardo Toledo, Eduardo and Valentijn, Anthony and Cox, Helen and Pertinez, Henry and Curley, Paul and Arshad, Usman and Rajoli, Rajith Kumar Reddy and Rannard, Steve and Stewart, James P and Owen, Andrew},
title = {Ronapreve (REGN-CoV; casirivimab and imdevimab) reduces the viral burden and alters the pulmonary response to the SARS-CoV-2 Delta variant (B.1.617.2) in K18-hACE2 mice using an experimental design reflective of a treatment use case},
journal = {Microbiology Spectrum},
year = {2024},
doi = {10.1128/spectrum.03916-23}
}
EUVIMED